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osting by EAbstract A 2-year-old healthy child presented with progressive unilateral proptosis.
Complete work up including: general examination, detailed ophthalmic evaluation and radiolog-
ical imaging were done. He underwent orbital exploration via anterior orbitotomy incision and deb-
ulking of the tumor was done.
The histopathological examination conﬁrmed the diagnosis of orbital ganglioneuroma.
Ganglioneuroma is an unusual benign tumor of neuroplastic origin with extremely rare orbital
involvement with only one prior reported case in a youth. The tumor is slow growing and non-
metastasizing. Biopsy is necessary to differentiate it from the malignant neuroblastoma and excision
is usually curative.
ª 2010 King Saud University. All rights reserved.1. Introduction
Ganglioneuroma is a rare benign tumor of neuroblastic origin
which can grow wherever sympathetic nervous tissue is found.
In addition to its association with metastatic neuroblastoma,
ganglioneuroma has been associated with neuroﬁbromatosis
type 1 and multiple endocrine neoplasia. Orbital involvement
is extremely rare with only one prior reported case in a youth.loplastic and Orbit Division,
.O. Box 7191, Riyadh 11462,
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lsevierWe report here a case of primary orbital ganglioneuroma in a
pediatric young healthy male patient along with imaging and
histopathological ﬁndings along with relevant literature
review.2. Case report
A 2-year-old Saudi boy presented to emergency room of King
Khaled Eye Specialist Hospital (KKESH) with history of
slowly progressive proptosis of the left eye of 2 months dura-
tion. He was a product of normal pregnancy and delivery with
normal growth and development, and has no prior history of
ocular trauma or surgery. His family history was non-
contributory.
On physical examination the child was healthy with no
obvious dysmorphic features. He was able to ﬁx and follow
in both eyes. He had 3–4 mm of left eye proptosis with some
inferior globe displacement (Fig. 1) but full extra ocular move-
ment. On biomicroscopy, the eye was quite with normal ante-
rior segment exam with regular and reactive pupil. His fundus
Figure 1 Clinical photograph prior to surgery showing proptosis
of the left eye.
Figure 3 Axial unenhanced CT scans demonstrate low attenu-
ation and homogeneous mass with slight to moderate patchy
homogeneous enhancement.
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tion showed the presence of two small cutaneous neuroﬁbro-
mas in scalp area but no cafe´ au laut spots.
CT scan and MRI of brain and orbit showed well deﬁned,
well circumscribed, homogenous extraconal soft tissue mass
occupying most of the superior orbital area, measuring
3.2 · 1.5 cm (Figs. 2 and 3). The mass was causing inferotem-
poral left globe displacement. This lesion showed minimal
enhancement with contrast without evidence of calciﬁcation
or bony destruction. MRI revealed a lobulated neoplasm of
the right superior orbit that molded around the globe. The
neoplasm was enhanced with contrast (Fig. 4). Abdominal
ultrasound, CT scan of chest, abdomen and pelvis were
normal.
Orbital exploration performed through an anterior orbitot-
omy via lid crease incision revealed a circumscribed lesion with
white–yellow surface without necrosis (Fig. 5). Incisional
biopsy and debulking was performed. On gross examination,
the excised mass measured 20 · 12 · 10 mm. HistopathologicalFigure 2 Coronal unenhanced CT scans demonstrate low
attenuation and homogeneous mass.
Figure 4 Sagital view of an orbital T1-weighted magnetic
resonance image showing a well-deﬁned, lobulated mass with
ﬁbrous septations without invasion of the bone.examination revealed scattered nests of mature ganglion cells
within a matrix of proliferating spindle cells (representing
Schwann cells) which led to the diagnosis of Ganglioneuroma
(Fig. 6). There were no features of malignancy such as hyper-
cellularity, necrosis or atypia. Immunohistochemical staining
was positive for S-100 protein stain (Fig. 7).
Postoperatively, the patient had a smooth course. Six
months after his surgery, the patient had no proptosis. His
MRI study showed residual mass which measured
1.6 · 1.2 cm with no signs of progression.
3. Discussion
Ganglioneuroma is a rare benign tumor of neuroblastic origin
which usually originates from neural crest sympathogonia
Figure 5 Gross photograph of the neoplasm showing a circum-
scribed lesion with a variegated tan-white surface lacking necrosis.
Figure 6 Hematoxylin–eosin staining showing mature ganglion
cells within a neuroﬁbrillary matrix and no neuroblastoma
(original magniﬁcation 200·).
Figure 7 Immunohistochemical stains showed ganglion cells
exhibiting strong cytoplasmic positivity S-100 protein.
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with neuroblastoma, ganglioneuromas and ganglioneuroblas-
tomas are collectively known as neuroblastic or neurogenic
tumors.These tumors can grow wherever sympathetic nervous tissue
is found. The most common sites involved are posterior medi-
astinum (41%), retroperitoneum (37%), adrenal gland (21%)
and neck (8%) (Geoerger et al., 2001). Ganglioneuromas usu-
ally occur in adolescents and young adults (40–60%), but indi-
viduals of all ages can be affected. Ganglioneuromas are more
frequent in older children with median age of diagnosis between
7 and 10 years (Lonergan et al., 2002). In addition to its associ-
ation with metastatic neuroblastoma, ganglioneuroma has been
associated with neuroﬁbromatosis type 1 and multiple endo-
crine neoplasia (MEN) (Geraci et al., 1998; Lora et al., 2004).
Orbital involvement is extremely rare. A single reported
case of orbital ganglioneuroma has been described in a 15-
year-old healthy boy who had history of chronic proptosis
for 4 years (Choi et al., 2009). To the best of our knowledge,
this may represent the second case of primary orbital ganglio-
neuroma in a young healthy patient.
Ganglioneuromas may arise de novo or in patients who
have had chemotherapy for metastatic neuroblastoma. A single
case was reported for a 12-year-old boy who had history of
stage IV neuroblastoma which was treated with chemotherapy
10 years prior to developing ganglioneuroma in the orbit (Can-
non et al., 2004). Other cases of ganglioneuroma with orbital
extension from adjacent sinuses or optic chiasm or cranial por-
tion of optic nerve have also been reported (Choi et al., 2009;
Cannon et al., 2004; Piquet et al., 1976; Cogan et al., 1961).
Neuroblastic tumors can be broadly subcategorized as neu-
roblastoma, ganglioneuroblastoma, or ganglioneuroma (Can-
non et al., 2004). The three tumors differ in their degree of
cellular and extracellular maturation; immature tumors tend
to be aggressive. The most benign tumor is the ganglioneu-
roma, which is composed entirely of neural elements, including
mature ganglion cells and Schwannian stroma and does not
contain neuroblasts, intermediate cells, or mitotic ﬁgures. Gan-
glioneuroblastoma is composed of both mature gangliocytes
and immature neuroblasts and has intermediate malignant po-
tential. Neuroblastoma is the most immature, undifferentiated
and malignant tumor of the three (Lonergan et al., 2002). Gan-
glioneuromas usually enlarge slowly; rapid growth should raise
suspicion for a poorly differentiated neoplasm such as neuro-
blastoma (Cannon et al., 2004).
Ganglioneuroma most often manifests as an asymptomatic
mass discovered on a routine radiographic study, such as a
chest or abdomen radiograph (Lonergan et al., 2002). Some-
times ganglioneuroma may cause local mass effect and patient
may present with cough, abdominal pain, or dyspnea. There are
no speciﬁc diagnostic signs or symptoms discriminating gan-
glioneuroma and neuroblastoma tumors (Geoerger et al.,
2001). In rare cases, ganglioneuroma secretes sufﬁcient quanti-
ties of vanillylmandelic acid (VMA) or homovanillic acid
(HVA) to manifest with ﬂushing and other symptoms of
catecholamine excess (Lucas et al., 1994). Although elevated
catecholamine production by neuroblastoma and ganglioneu-
roblastoma occurs in 90–95% of patients, elevated levels may
also be seen in ganglioneuroma and therefore do not aid in dis-
criminating between the three (Geoerger et al., 2001). In the
largest series of ganglioneuroma to date (49 cases), 37% of
the patients had elevated VMA or HVA levels (Geoerger
et al., 2001). Moreover, ganglioneuroma, like neuroblastoma
and ganglioneuroblastoma, may accumulate metaiodobenzyl-
guanidine (MIBG) which has been reported in up to 57% of
ganglioneuromas in one study (Geoerger et al., 2001).
104 H. Al-Khiary et al.Magnetic resonance imaging (MRI) and computed tomog-
raphy (CT) scanning are the preferred methods for imaging
ganglioneuromas and ganglioneuroblastomas (Lonergan
et al., 2002). Nonenhanced CT scanning reveals a homoge-
neous mass with less attenuation than muscle. CT may show
calciﬁcations in two-thirds of cases. Calciﬁcation is typically
ﬁne and speckled but may be coarse (Ichikawa et al., 1996;
Johnson et al., 1997). MRI is the modality of choice for eval-
uating the extension of the lesion. Ganglioneuromas appear
homogeneous on MRIs and have relatively intermediate signal
intensity on all pulse sequences.
Ganglioneuromas, as fully differentiated neoplasms, do not
have the capability to metastasize, so extensive surgical resec-
tions or chemotherapy is not normally necessary (Cannon
et al., 2004). It is important that adequate surgical sampling
is obtained to allow sufﬁcient histologic analysis and to assure
no neuroblastic cellular elements are present as done in our
case. Excision may be considered when the pathologic diagno-
sis is uncertain or visual function is compromised by the neo-
plasm (Cannon et al., 2004).
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